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Abstract Recent evidence has demonstrated that endothe-
lial cells can have a remarkable plasticity. By a process
called Endothelial-to-Mesenchymal Transition (EndMT)
endothelial cells convert to a more mesenchymal cell type
that can give rise to cells such as fibroblasts, but also bone
cells. EndMT is essential during embryonic development
and tissue regeneration. Interestingly, it also plays a role in
pathological conditions like fibrosis of organs such as the
heart and kidney. In addition, EndMT contributes to the
generation of cancer associated fibroblasts that are known
to influence the tumor-microenvironment favorable for the
tumor cells. EndMT is a form of the more widely known
and studied Epithelial-to-Mesenchymal Transition (EMT).
Like EMT, EndMT can be induced by transforming growth
factor (TGF)-β. Indeed many studies have pointed to the
important role of TGF-β receptor/Smad signaling and
downstream targets, such as Snail transcriptional repressor
in EndMT. By selective targeting of TGF-β receptor
signaling pathological EndMT may be inhibited for the
therapeutic benefit of patients with cancer and fibrosis.
Keywords Angiogenesis.Cancer associated fibroblasts.
Endothelial cells.EndMT.Fibrosis.Epithelial-to-
mesenchymal transition.Fibrodysplasia ossificans
progressiva.TGF-β
Abbreviations
ActR Activin receptor
ALK Activin receptor-like kinase
BMP Bone Morphogenetic Protein
CAF Cancer-Associated Fibroblast
E-Cadherin Epithelial-cadherin
EMT Epithelial-to-Mesenchymal Transition
EndMT Endothelial to Mesenchymal Transition
FOP Fibrodysplasia Ossificans Progressiva
Id Inhibitor of differentiation/DNA binding
IPF Idiopathic Pulmonary Fibrosis
MI Myocardial infarction
N-Cadherin Neural-Cadherin
PAI-1 Plasminogen Activator Inhibitor-1
SMA Smooth Muscle cell Actin
Smad Small phenotype and Mothers
Against Decapentaplegic related protein
TGF-β Transforming Growth Factor-β
TGFβR Transforming Growth Factor-β receptor
VE-Cadherin Vascular-endothelial cadherin
Introduction
Complex body architecture is reliant on efficient supply of
oxygen and nutrients to all tissues. The vascular system
achieves this task efficiently via a highly branched network of
blood vessels. The inner layer of blood vessels is lined with a
thin layer of endothelial cells, stabilized by a basal lamina
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lial cells however do perform additional functions besides
lining the vessel wall. One very interesting example that is
emerging from recent studies is the transition of endothelial
cells into mesenchymal cells (Goumans et al. 2008). This form
of endothelial cells plasticity is called endothelial-to-
mesenchymal transition (EndMT) and is the subject of this
review.
During EndMT, endothelial cells delaminate from the
organized layer of cells in the vessel-lining and migrate away
possibly invading the underlying tissue. The mesenchymal
phenotype ischaracterized bythe acquisition ofmesenchymal
markers such as smooth muscle cell actin (SMA) and Neural
(N)-Cadherin and the complementary loss of endothelial
marker such as CD31/Pecam-1 and Vascular-Endothelial
(VE)-Cadherin. In addition, the endothelial cells lose their
cell-cell junctions and gain migratory and invasive capacity.
Although discovered in the process of heart-development
(Markwald et al. 1975), the mechanism of EndMT has now
been implicated in a wide variety of pathological conditions
like fibrosis of several organs as well as in cancer (Potenta et
al. 2008).
EndMT is related to the more widely known mechanism of
epithelial-to-mesenchymal transition (EMT). EMT allows a
polarized epithelial cell, which normally interacts with base-
ment membrane via its basal surface, to undergo multiple
changes that enable it to assume a mesenchymal cell
phenotype, which includes enhanced migratory capacity,
invasiveness and elevated resistance to apoptosis. One of the
molecular hallmarks of EMT is the loss of Epithelial (E)-
cadherin expression that is frequently mediated by the
upregulation of Snail transcription factor family members.
EMT can occur in many epithelial cells and is, as EndMT, a
critical process in embryonic development (Thiery and Slee-
man 2006). In addition EMTis thought to be very important in
cancer development since an epithelial cell needs to lose cell-
celljunctionsbeforeitwouldbeabletoinvadethesurrounding
tissue and migrate away ultimately leading to metastasis.
As shown for epithelial plasticity (Xu et al. 2009;
Miyazono 2009) TGF-β signaling also plays an important
role in regulating endothelial plasticity. Therefore we shall
first discuss TGF-β receptor signaling in controlling
endothelial cell function. Subsequently, we will focus on
the role of endothelial cell plasticity in health and disease.
TGF-β signaling
TGF-β is one of the best known members of a large family of
secreted pleiotrophic growth factors. Other members of the
family include the bone morphogenetic proteins (BMPs) and
activins.Manyofthese cytokineshavevitalrolesinnumerous
processes during development, but also in maintenance of
tissue homeostasis and tissue repair in the adult (Massague
1998). Not unexpectedly, they also have roles in pathological
conditions like cancer, vascular diseases and fibrosis (ten
Dijke and Arthur 2007; Blobe et al. 2000).
Members of the TGF-β family mediate their effects by
binding specific transmembrane receptors at the cell-
membrane (Feng and Derynck 2005). They bind a complex
oftwotypeIandtwotypeIIserine/threoninekinasereceptors.
Uponligandinducedheteromericcomplexformation,thetype
I receptor is phosphorylated by the type II receptor. There are
seven differenttypeI receptors (ALK1 toALK7)(also known
as activin receptor-like kinases (ALK)) and five type II
receptors (activin receptor type IIA (ActRIIA), activin
receptor type IIB (ActRIIB), BMP type II receptor (BMPRII),
TGF-β type II receptor (TGFβRII) and AMH type II receptor
(AMHRII)).Differentligandscanbinddifferentcombinations
of type I and type II receptor thereby creating specificity of
signaling. TGF-β signals mostly via ALK5 and TGFβRII,
activins via ALK4 with ActRIIA and ActRIIB, and BMPs
signal via ALK1, 2, 3 and 6 together with BMPRII, ActRIIA
and ActRIIB. For regulation of endothelial function by TGF-
β, ALK1 and ALK5 signaling are most important (van
Meeteren et al. 2011).
After binding of the ligand the type I receptor
phosphorylates specific transcription factors called recep-
tor regulated (R)-Smads. Upon activation by type I
receptors, R-Smads form heteromeric complexes with
the common mediator (Co)-Smad (Smad4) and these
heteromeric complexes accumulate into the nucleus,
where they regulate the transcription of specific target
genes (Moustakas and Heldin 2009).
Inhibitory Smads (I-Smads) inhibit the activation of
R-Smads by competing for type I receptor interaction
and by recruiting phosphatases and ubiquitin ligases to
the activated receptor complex leading to dephosphory-
lation or proteosomal degradation of the receptor
complex (Itoh and ten Dijke 2007). R-Smads can be
divided in 2 groups based on the type I receptor that is
activating them. The first group consists of Smad1, 5 and
8 and these are activated by ALK1, 2, 3 and 6. The second
group contains Smad2 and 3 and is activated by ALK4, 5
a n d7 .I na d d i t i o nt oS m a ds i g n a l i n gT G F - β and BMP
signaling can result in activation of pathways where
Smads are not involved. Non-Smad pathways include
various branches of MAP kinase pathways, Rho-like
GTPase signaling pathways, and PI3K/AKT pathways
(Zhang 2009; Moustakas and Heldin 2005).
Co-receptors are receptors that do not signal by themselves
since they lack intracellular enzymatic domains such as
kinase-domains. For TGF-β signaling co-receptors endoglin
and betaglycan (also called TGF-β receptor III) have been
identified. Both receptors are structurally related and have a
small intracellular tail and a large extracellular domain.
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hence its name endoglin (ten Dijke et al. 2008).
To regulate the activation state of endothelial cells TGF-
β can differentially activate two type I receptors, ALK1 and
ALK5 (Fig. 1) (Oh et al. 2000; Goumans et al. 2002).
ALK5 is ubiquitously expressed in most tissues, but ALK1
expression is typically restricted to endothelial cells. TGF-β
induced ALK5 signaling leads to Smad2 and Smad3
phosphorylation resulting in inhibition of angiogenesis by
inhibiting endothelial cell proliferation, migration and
organization (Goumans et al. 2002, 2003). The ALK5
kinase inhibitor SB-431542 facilitated proliferation and
sheet formation of embryonic stem cell derived endothelial
cells and in fetal mouse metatarsal assays (Watabe et al.
2003; Liu et al. 2009). In addition, SB-431542 upregulated
the expression of claudin-5, an endothelial specific compo-
nent of tight junctions, suggesting a role of ALK5 signaling
in regulating vascular permeability (Watabe et al. 2003).
Indeed, ALK5 has been reported before to be important for
TGF-β induced permeability and cytoskeletal remodeling
of endothelial cells (Birukova et al. 2005). In summary,
ALK5 signaling results in keeping endothelial cells in a
quiescent state.
In contrast, TGF-β induced ALK1 signaling activates
Smad1 and Smad5 leading to endothelial cell proliferation,
migration and organization (Goumans et al. 2003). An
important intracellular effector of ALK1 is Inhibitor of
Differentiation/DNA binding (Id)1; its upregulation was
shown to be required for TGF-β/ALK1-induced endothelial
cell migration and tube formation (Goumans et al. 2002).
However, inhibitory effects of ALK1 signaling on endothe-
lial cells have also been reported (David et al. 2007;
Lamouille et al. 2002; Mallet et al. 2006). The effect of
ALK1 is likely dependent on cellular context.
Although ALK1 and ALK5 have divergent effects on
endothelial cells they do interact with each other physically.
ALK5-deficient endothelial cells are not only defective in
ALK5 signaling but also show impaired ALK1 responses;
ALK5 was found to be essential for recruitment of ALK1
into a TGF-β receptor complex, and the kinase activity of
ALK5 is essential for full ALK1 activation (Goumans et al.
2003). On the other hand, ALK1 can directly antagonize
ALK5 signaling at the level of Smads (Oh et al. 2000;
Goumans et al. 2002). In conclusion, the cross-talk between
ALK1 and ALK5 signaling provides endothelial cells with
a sophisticated mechanism to fine tune endothelial function
(Fig. 1).
The TGF-β co-receptors endoglin and betaglycan can
both be expressed by endothelial cells. Endoglin positive
but betaglycan negative endothelial cells are only respon-
sive to TGF-β isoforms 1 and 3 but not to isoform 2
(Cheifetz et al. 1990). In endothelial cells that express both
co-receptors it was shown that endoglin can form a
complex with betaglycan and the TGF-β receptor complex
simultaneously (Wong et al. 2000).
Signals controlling EndMT
Many endothelial cells can be induced to undergo EndMT
in cell culture experiments. This has opened the opportunity
to study the signaling mechanism in EndMT. To induce
EndMT of endothelial cells, they are often stimulated with
TGF-β or Notch ligands (Frid et al. 2002; Ishisaki et al.
2003; Timmerman et al. 2004; Noseda et al. 2004; Zeisberg
et al. 2007b; Zeisberg et al. 2007a).
The molecular mechanism behind TGF-β induced
EndMT has been found to involve the Snail family of
transcription repressors. In mouse embryonic stem cell
derived endothelial cells TGF-β induced EndMT and
expression of Snail. This upregulation of Snail by TGF-β
was shown to be dependent on the activation of Smad,
MEK, PI3K and p38 MAPK by TGF-β (Medici et al.
2011). Subsequent knockdown of Snail blocked the TGF-β
induced EndMT (Kokudo et al. 2008). Although over-
expression of Snail was sufficient to induce EMT (Cano et
Fig. 1 TGF-β signaling in endothelial cells. TGF-β can bind to two
distinct TGF-β type II/type I receptor complexes in which TGF-β
type II receptor (TβRII) is a common component and two different
type I receptors, i.e. activin receptor-like (ALK)5 and ALK1
determine signaling specificity. Whereas activation of ALK5 will
inhibit endothelial cell proliferation, ALK1 will elicit opposite
responses. Endoglin is an auxiliary receptor that modulates TGF-β
signaling responses, i.e. it stimulates TGF-β/ALK1 but inhibits TGF-
β /ALK5 signaling
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The inhibitor of Snail, GSK-3β, needs to be inhibited by
phosphorylation by kinases such as AKT to induce EndMT
(Medici et al. 2011).
As mentioned above Notch can, as TGF-β,u s e di nv i t r ot o
induce EndMT in endothelial cells in vitro. In this Notch
induced EndMT the Snail family member Slug has been
shown tobe important(Leong etal. 2007). Snail and Slug are
known to repress the expression of VE-cadherin (Lopez et al.
2009). Since VE-cadherin is essential for endothelial cell-cell
junctions this obviously could provide a link to a mechanism
by which EndMToccurs. A different factor involved in TGF-
β induced EndMT was shown to be plasminogen activator
inhibitor-1 (PAI-1). Although elevated levels of PAI-1 are
implicated in tissue fibrosis (Ghosh and Vaughan 2011), lack
of PAI-1 in the heart is associated with the development of
cardiac fibrosis in aged mice (Ghosh et al. 2010). It was
shown that in the PAI-deficient endothelial cells of these
mice both Smad and non-Smad TGF-β signaling is
spontaneously activated. This spontaneous activation leads
to EndMT and subsequently the fibrosis observed in these
animals (Ghosh et al. 2010). In addition, it was recently
shown that c-Abelson tyrosine kinase (c-Abl) and Protein
Kinase C (PKC)-δ are crucial for TGF-β-induced EndMT
and therefore that imatinib mesylate and rottlerin (inhibitors
of c-Abl and PKC-δ, respectively) might be effective
therapeutic agents for fibroproliferative pathologies in which
EndMT plays a role (Li and Jimenez 2011).
It has also been reported that pathways other than TGF-
β can lead to EndMT. In myocardial infarction (MI) for
example, canonical (β-catenin-dependent) Wnt signaling is
induced 4 days after experimental MI in the subepicardial
endothelial cells and perivascular cells. Coincidently with
canonical Wnt activation EndMT was also triggered after
the infarction. In addition, canonical Wnt signaling induced
mesenchymal characteristics in cultured endothelial cells,
suggesting a direct role of canonical Wnt signaling in
EndMT (Aisagbonhi et al. 2011).
EndMT in development
EndMT was originally discovered in the embryonic heart
during studies on heart development (Markwald et al.
1975). In heart development, endothelial cells lining the
endocardial cushions undergo EndMT (Fig. 2). These cells
subsequently invade the underlying tissue and participate in
the formation of the septa and valves of the heart
(Eisenberg and Markwald 1995). Studies from knockout
mice have shown subsequently that signals directing
EndMT in heart development include multiple TGF-β
isoforms and receptors (Goumans and Mummery 2000).
Forexampleitwasshownthatendoglin,aTGF-βco-receptor,
is required cell autonomously for EndMT during formation of
theendocardialcushions(Nomura-Kitabayashietal.2009). In
the embryonic heart the endothelial cells that undergo TGF-
Fig. 2 TGF-β in endothelial
cell plasticity. TGF-β can stim-
ulate the transition of endotheli-
al into mesenchymal cells.
EndMT is a complex process
that involves disruption of
polarized endothelial morpholo-
gy into cells with spindle-shaped
morphology with formation of
actin stress fibers. Furthermore
EndMT results in reduced
cell–cell junctions through de-
localization and downregulation
of VE-cadherin and PECAM,
increased cellular motility and
expression of mesenchymal
makers, such a-SMC actin, N-
Cadherin and FSP-1. EndMT
plays an important role in
development, regeneration and
pathological processes, such as
fibrosis and tumor stroma
formation
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devoid of primary cilia (Van der Heiden et al. 2008). Egorova
et al recently showed that TGF-β/ALK5 signaling is
activated by blood flow in these endothelial cells (Egorova
et al. 2011b), and lack of primary cilia primes endothelial
cells for EndMT, thereby linking primary cilia with flow-
related endothelial differentiation (Egorova et al. 2011a).
Role of EndMT in cancer
Fibroblasts are one the most abundant cell type in the
microenvironment of tumors, being particularly prominent
in carcinomas of colon, breast, pancreas, and prostate.
There is substantial evidence that cancer-associated fibro-
blasts (CAFs) contribute to tumor growth and metastasis.
This is mediated by the release of classical growth factors
such as TGF-β, epidermal growth factor, hepatocyte growth
factor, as well as a range of chemokines that influence
diverse aspects of tumor cell behavior (Allen and Louise
Jones 2011).
CAFs form a heterogeneous population, most likely
related to their diverse origin. Whereas activation of local
stromal fibroblasts has traditionally been considered the
major source of CAFs (Kalluri and Zeisberg 2006), recently
it was shown that EndMT is another unique source of CAFs
(Fig. 2) (Zeisberg et al. 2007a). In this study EndMT in
tumors was reported in two different mouse models of
cancer and demonstrated that a substantial proportion of
CAFs in these models arise through EndMT. The CAFs
were shown to co-express the endothelial marker CD31
along with one of the mesenchymal markers, fibroblast
specific protein (FSP)1, or α-smooth muscle actin (αSMA).
Approximately, 40% of FSP1-positive CAFs were also
found to be CD31 positive. To study the origin of the CAFs
in more detail, tumors were grown in Tie2-Cre;R26R-lox-
STOP-lox-lacZ transgenic mice, a reporter strain in which
all cells of endothelial origin can be irreversibly labeled
with lacZ.I n3 0 %o ft h eC A F si nt u m o r so ft h e s e
transgenic mice LacZ was detected making the authors
conclude that the CAFs originated from endothelial cells
(Zeisberg et al. 2007a). Since Tie2 is however also
expressed in the hematopoietic lineage it is technically also
possible that the lacZ positive CAFs originate from these
cells (Tang et al. 2010; Gitler et al. 2004).
These studies suggest that EndMT is an important
mechanism for CAF recruitment to the tumour stroma.
Since TGF-β signaling is a known mediator of EndMT and
TGF-β is abundantly expressed in many different tumors
(Zeisberg et al. 2007a), EndMT may be mediated by TGF-
β produced in the tumor. Yet, the molecular mechanism of
EndMT in tumors has not yet been specifically studied, but
is to be expected to involve similar pathways as in fibrosis.
EndMT in tissue fibrosis
Fibrosis is an essential process of proper wound healing. In
many pathological conditions however deregulated or
excessive fibrosis occurs. TGF-β signaling is involved in
physiological fibrosis in wound healing. Therefore it is not
surprising that TGF-β signaling also plays an important
role in pathological fibrosis.
The predominantcellularmediatorsoffibrosisareassumed
to be (myo)fibroblasts, not only in heart fibrosis but also in
fibrosis of organs such as lung, kidney, and the liver. Fibrosis
of all these organs share similar pathways. The origin of these
(myo)fibroblasts may, besides resident interstitial fibroblast,
be cells derived from the bone marrow as well as fibroblastic
cells that have transdifferentiated from cells of epithelial
origin.Moreinterestingly,these cells canalsobederivedfrom
endothelial cells that have undergone EndMT (Fig. 2).
In the kidney for example it was shown that EndMT can
generate myofibroblasts in early diabetic renal fibrosis. Using
endothelial-lineage tracing with Tie2-cre; LoxP–eGFP trans-
genic mice a significant number of interstitial α-smooth
muscle actin-positive cells (myofibroblasts) were shown to
be of endothelial origin in fibrotic kidneys from mice with
streptozotocin-induced diabetic nephropathy. This indicated
that EndMT can contribute to the early progression of
diabetic nephropathy (Li et al. 2009;K i z ue ta l .2009).
Earlier it was already shown that fibroblasts expressed the
endothelial marker CD31 in three different mouse models of
renal disease: streptozotocin-induced diabetic nephropathy,
unilateral ureteral obstructive nephropathy, and a mouse
model of Alport syndrome (Zeisberg et al. 2008). Approx-
imately 30% to 50% of fibroblasts formed in the kidneys of
these models co-expressed the endothelial marker CD31 and
the fibroblast/myofibroblast markers FSP1 and/or αSMA
(Zeisberg et al. 2008). Since TGF-β is stimulating EndMT it
is not surprising that interference with TGF-β signaling has
been reported to inhibit EndMT and the subsequent kidney
fibrosis. First it was reported that Smad3 conditional
knockout mice are resistant to streptozotocin-induced renal
fibrosis and tubulointerstitial fibrosis in unilateral urethral
obstruction models (Fujimoto et al. 2003;W a n ge ta l .2007;
Sato et al. 2003). Subsequently it was shown that a Smad3
inhibitor delays the early development of streptozotocin-
induced diabetic nephropathy due to a blockade of EndMT
(Li et al. 2010).
Likewise in the lung, fibrosis can cause serious
pathological conditions such as idiopathic pulmonary
fibrosis (IPF). IPF is characterized by progressive obliter-
ation of normal alveolar lung architecture and replacement
by fibrotic tissue. The result is declining lung function,
progressive dyspnea, and ultimately death within 3 to
5 years of diagnosis (Nataraj et al. 2010). Hashimoto et al
have demonstrated that pulmonary capillary endothelial
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in pulmonary fibrosis (Hashimoto et al. 2010). They
showed this by bleomycin-induced lung injury in mice
where they found, using lineage tracing methods that the
fibroblasts originated from the endothelial cells. Interest-
ingly they also found a dependence on Ras for completion
of EndMT. Only treatment with TGF-β in combination with
activated Ras induced a persistent morphological change
and suppression of endothelial markers consistent with
EndMT (Hashimoto et al. 2010).
Endothelial-to-mesenchymal transition in cardiac
fibrosis
In cardiac fibrosis the heart valves abnormally thicken due to
inappropriate proliferation of cardiac fibroblasts and of
disruption of normal myocardial structure through excessive
deposition of extracellular matrix (Krenning et al. 2010).
Several studies have given evidence for the role of EndMT in
cardiac fibrosis. For example Zeisberg et al. performed
lineage analysis to trace the origin of the fibroblasts in
cardiac fibrosis (Zeisberg et al. 2007b). Cardiac fibrosis was
induced by exposing the heart to pressure overload for
5 days via aortic banding. Analysis of the fibrotic lesions
revealed the presence of fibroblasts that originated from
endothelial cells. This study elegantly shows that endothelial
cells can undergo EndMT and contribute to the total pool of
cardiac fibroblasts, similar as in formation of the aterioven-
tricular cushion in embryonic development.
TGF-β signaling stimulates the collagen-producing cardiac
fibroblast and has therefore been implicated in the pathogen-
esisofcardiacfibrosis(KhanandSheppard2006). Progression
of cardiac fibrosis is furthermore stimulated by a Smad3-
dependent TGF-β signaling pathway inducing EndMT. In
Smad3 heterozygous mice cardiac fibrosis was significantly
reduced and associated with a decrease in the number of
endothelial-derived fibroblasts (Dobaczewski et al. 2010;
Bujak et al. 2007). In a different study BMP-7 inhibited
EndMT and conserved the endothelial phenotype. The
systemic administration of exogenous BMP-7 significantly
inhibited EndMT and the progression of cardiac fibrosis in
mouse models of chronic allograft rejection and pressure
overload (Zeisberg et al. 2007b). Thus, although BMP
cooperates with TGF-β in inducing EndMT during cushion
formation, it is an antagonist in the TGF-β fibrotic pathway,
preserving the endothelial phenotype and preventing fibrosis.
Targeting TGF-β in fibrotic diseases
With EndMT (and EMT) contributing to tissue fibrosis
progression and TGF-β as pivotal mediator of this response
and also inducer of extracellular matrix deposition, this
opens possibilities to intervene with fibrosis by targeting
TGF-β. Several clinical trials on fibrosis with anti-TGF-β
agents have been done or are currently running. For
example in skin fibrosis a clinical trial is testing the effect
of the synthetic peptide P144 (ClinicalTrials.gov Identifier:
NCT00781053). P144 encodes a part of the ligand (TGF-β)
binding domain of betaglycan and can block TGF-β
activity. In animal models P144 inhibited carbon tetrachlo-
ride induced liver fibrosis and more importantly it inhibited
bleomycin induced skin fibrosis (Ezquerro et al. 2003).
CAT-152 (Lerdelimumab) is a fully human TGF-β2
neutralizing antibody with high affinity for TGF-β2 and
lower affinity for TGF-β3 (Thompson et al. 1999). In
rabbits it was capable of inhibiting scarring after glaucoma
surgery (Mead et al. 2003). In the first clinical trials, CAT-
152 showed possible effects in reducing scar formation in
intractable glaucoma patients that received a trabeculec-
tomy (Siriwardena et al. 2002). Disappointingly in larger
phase III clinical trials these results could not be confirmed
however (Khaw et al. 2007).
Systemic sclerosis is a disease in where the dermal layer
of the skin undergoes fibrosis. In addition systemic
sclerosis results in inflammatory responses, vascular
changes and loss of function of internal organs due to
scarring and extracellular matrix deposition. In a phase I/II
trial CAT-192, a TGF-β1 neutralizing antibody did not
show effect on early stage diffuse cutaneous systemic
sclerosis, together with more adverse events occurred in
the CAT-192 treated groups (ClinicalTrials.gov Identifier:
NCT00043706) (Denton et al. 2007). Nevertheless this
antibody is now being tested in patients with myelofibrosis
(ClinicalTrials.gov Identifier: NCT01291784).
GC2008 or Fresolimumab which is the humanized
version of the pan-TGF-β neutralizing antibody 1D11 is
also tested in clinical trials. These trials also treat patients
with diffuse systemic sclerosis (ClinicalTrials.gov Identifi-
er: NCT01284322).
EndMT leading to loss of endothelial function
As described above the result of EndMT in pathological
conditions is fibrosis because of the generation of fibro-
blasts and excessive extracellular matrix. However EndMT
also leads to the loss of endothelium. The loss of
endothelial function can lead to badly perfused tissue and
subsequent tissue damage. For example following traumatic
spinal cord injury, significant vascular disruption occurs at
the site(s) of injury. This interruption of vascular support is
thought to be a key mediator of multiple secondary injury
cascades, all of which contribute to loss of functional tissue.
It was demonstrated that in response to spinal ischemia/
182 Cell Tissue Res (2012) 347:177–186reperfusion injury TGF-β-responsive genes in the endothe-
lial cell compartment were early and robustly transcription-
al activated (Benton et al. 2009). Given the known effects
of TGF-β on endothelial cells it is attractive to speculate
that the loss of endothelial functions, such as increased
permeability of the endothelium in spinal cord injury is due
to increased TGF-β signaling and conversion of endothelial
cells to a more fibroblastic phenotype.
Endothelial transdifferentiation is not limited to fibrosis
Other than differentiation towards myofibroblasts endothe-
lial cells can also differentiate to other cell types.
Interestingly TGF-β s i g n a l i n gw a ss h o w nt op l a ya n
important role also in these transdifferentiation processes.
Fibrodysplasia ossificans progressiva (FOP) is a severely
debilitating disorder caused by an activating mutation in the
BMP type I receptor, ALK2 (Shore et al. 2006). In FOP-
patients acute inflammation causes heterotopic ossification
in soft tissues at nearly any site in the body (Kaplan et al.
2008). The source of the ossifying cells was previously
unknown but Medici et al. showed that bone and cartilage
cells from lesions of people with FOP and mice with
mutant ALK2 expressed the endothelial markers Tie2 and
von Willebrand factor. This suggests an endothelial origin
of the ectopic mesenchymal cells that form the heterotopic
tissues (Horwitz 2010; Medici et al. 2010). Furthermore,
human endothelial cells treated with BMP4 or TGF-β2, to
activate endogenous ALK2, undergo EndMT resulting in
mesenchymal stem cells. These mesenchymal stem cells
may be of use in cell therapy to treat people in need of bone
and cartilage regeneration (Medici et al. 2010).
Not only endothelial cells lining the vessel wall have
been shown to be able to undergo EndMT. Also circulating
endothelial progenitor cells have been shown to undergo
EndMT. The conversion of these circulating endothelial
progenitor cells to smooth muscle-like progeny was also
shown to be stimulated by TGF-β (Moonen et al. 2010).
Endothelial plasticity also plays a role in the phenotype
of the three main types of endothelial cells; arterial, venous
and lymphatic. These 3 different phenotypes can be
superimposed, or reverted to, by subtle alterations in the
combination or in the expression levels of a few key
regulators (e.g. Notch signaling, COUP-TFII and Prox1)
(Johnson et al. 2008; You et al. 2005) (reviewed in (Oliver
and Srinivasan 2010). Furthermore also during sprouting
angiogenesis there are several different types of cells within
the growing sprout. Tip cells and stalk cells are fundamen-
tally different although they can revert to one and another
quickly (Jakobsson et al. 2010). These changes in endothe-
lial cell fates highlight again the once unappreciated
plasticity of endothelial cells.
Concluding remarks
Recent studies have revealed the remarkable plasticity of
endothelial cells. While initially met with skepticism (Tarin
et al. 2005), EMT (and therefore also EndMT) was gaining
acceptance. However, the concept of EMT/EndMT is
currently under intense discussion (Quaggin and Kapus
2011; Zeisberg and Duffield 2010), in particular as it relates
to kidney and liver fibrosis. Whereas early lineage tracing
studies demonstrated EMT/EndMT, new lineage tracing
experiments failed to do so (Humphreys et al. 2010). What
is clear is that epithelial/endothelial cells can undergo
morphological changes, i.e. demonstrate plastic behavior,
and that TGF-β drives this process. In pathological
situations like cancer and fibrosis, targeting of the TGF-β/
Smad signaling pathway may have therapeutic benefit and
should be further explored in experimental animal models
and clinical trials. Recent advances of (intravital) imaging
techniques should be applied in vivo studying diseases with
possible links to EMT/EndMT to see whether further
evidence of these processes can be obtained (Yoshino et
al. 2011). As mentioned above several clinical trials are
ongoing to test if anti-TGF-β therapy can inhibit patholog-
ical conditions, like fibrosis, in which endothelial (and
epithelial) plasticity plays an important role. If successful
not only many fibrotic pathological conditions but also the
generation of cancer associated fibroblasts might be
inhibited. This would lead to a less favorable micro-
environment for tumor growth and ultimately would help
to fight cancer in the clinic.
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